Clinical Trial Update: Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of BU-12, a Yttrium-90 labeled anti-CD19 antibody, in advanced relapsed or refractory acute lymphoblastic leukemia or chronic lymphocytic leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia

Drugs mentioned

• BU-12 (Yttrium-90 anti-CD19 antibody) (Yttrium-90 labeled anti-CD19 monoclonal antibody BU-12)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Leukemia | Phase 1 | Status: TERMINATED